For example, a recent phase II trial showed that Ipetekimab, an anti-IL-33 monoclonal antibody, improved asthma control, lung function, quality of life, and lowered blood eosinophil count (Wechsler et al., 2021). This evidence concerns the gene IL33 and asthma.